---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125921"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:57:58.080563+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q3 net loss $19.1M; neffy launch progressing; ALK deal $145M

## Summary
- Net loss of $19.1M for Q3 2024; total revenue of $2.1M including $0.6M neffy product revenue from one week of sales.
- Cash, equivalents & short-term investments $204.6M at Sept 30; pro forma $349.6M after $145M upfront from ALK-Abelló deal.
- FDA granted priority review for neffy 1mg sNDA; PDUFA date March 6, 2025 for children weighing 15-30 kg.
- Exclusive license with ALK-Abelló for neffy in Europe, Canada, etc.; total consideration up to $465M plus double-digit royalties.
- Over 5,700 HCPs reached, 1,700+ prescriptions submitted, and 1,000 allergists enrolled in neffy Experience Program since launch.

## SEC filing metadata
- accession: 0000950170-24-125921
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/0000950170-24-125921-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125921
- JSON: https://secwatch.observer/filing/0000950170-24-125921.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125921.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.